News

Biocon Biologics Expands Diabetes Portfolio With FDA Approval Of Kirstytm, The First And Only Interchangeable Rapid-Acting Insulin Aspart In The United States
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...
Preview: IQVIA Hldgs's Earnings
Analysts have given IQVIA Hldgs a total of 7 ratings, with the consensus rating being Neutral. The average one-year price target is $174.0, indicating a potential 8.32% upside.
IQVIA: Competition Is Creating More Challenges Over The Long Haul
IQVIA Holdings' results in Q1 2025 were good, surpassing analysts' estimations. Click here to find out why I rate IQV stock ...